Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RSV
Pharma
FDA signs off on GSK's Arexvy for at-risk adults ages 18-49
GSK has scored an FDA expansion for its RSV vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease.
Kevin Dunleavy
Mar 13, 2026 11:07am
Sanofi sanctioned over CEO's 'bold claims' about Pfizer vaccine
Feb 3, 2026 9:40am
GSK's long-acting asthma med wins CHMP backing
Dec 12, 2025 11:27am
Merck, Sanofi, AZ shots for RSV now under scrutiny by FDA
Dec 9, 2025 11:52am
Moderna outlines 3-year business strategy in bid to break even
Nov 20, 2025 2:54pm
Sanofi forms 'celebrity mom squad' for Beyfortus RSV campaign
Sep 10, 2025 12:42pm
